Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03462459 · ClinicalTrials.gov registry record · Phase 2

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

A Phase 2 study, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Phase 2
Development phase
79
Enrollment target

NCT03462459 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 79 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03462459, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Phase 2
Development phase
79 participants
Enrollment target

Study Summary

This study evaluates the efficacy of prophylaxis with oral vancomycin for preventing recurrent Clostridium difficile Infection (CDI) in patients who have experienced at least one CDI episode in the last 180 days and are receiving antibiotics for a non CDI condition. Participants will be randomized to receive either placebo or oral vancomycin in addition to their prescribed antibiotic therapy.

Interventions

  • DRUG Placebo
  • DRUG Vancomycin

Trial Details

FieldValue
Enrollment Target 79 participants
Start Date 2018-05-21
Est. Completion 2023-07-06
Phase Phase 2

Sponsor

University of Wisconsin, Madison

1,039 total trials

What the Registry Record Tells You About NCT03462459

The ClinicalTrials.gov registry entry for NCT03462459 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03462459 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03462459 about?

NCT03462459 is a clinical study titled "Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection". This study evaluates the efficacy of prophylaxis with oral vancomycin for preventing recurrent Clostridium difficile Infection (CDI) in patients who have experienced at least one CDI episode in the last 180 days and are receiving antibiotics for a non CDI condition. Participants will be randomized t...

What is the current status of trial NCT03462459?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2018-05-21. Estimated completion is 2023-07-06.

What interventions are being tested in trial NCT03462459?

The interventions under investigation include: Placebo (DRUG), Vancomycin (DRUG).

Who is sponsoring clinical trial NCT03462459?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.